Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Nephros (NEPH) Free Cash Flow (2016 - 2025)

Nephros has reported Free Cash Flow over the past 16 years, most recently at $230000.0 for Q4 2025.

Quarterly results put Free Cash Flow at $230000.0 for Q4 2025, down 82.36% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 434.35% YoY), and the annual figure for FY2025 was $1.6 million, up 400.73%.
Free Cash Flow for Q4 2025 was $230000.0 at Nephros, up from $99000.0 in the prior quarter.
Over the last five years, Free Cash Flow for NEPH hit a ceiling of $1.3 million in Q4 2024 and a floor of -$1.8 million in Q1 2022.
Median Free Cash Flow over the past 5 years was -$143500.0 (2021), compared with a mean of -$142200.0.
Biggest five-year swings in Free Cash Flow: plummeted 2247.44% in 2022 and later surged 577.66% in 2024.
Nephros' Free Cash Flow stood at -$335000.0 in 2021, then surged by 41.79% to -$195000.0 in 2022, then tumbled by 40.0% to -$273000.0 in 2023, then surged by 577.66% to $1.3 million in 2024, then crashed by 82.36% to $230000.0 in 2025.
The last three reported values for Free Cash Flow were $230000.0 (Q4 2025), $99000.0 (Q3 2025), and $994000.0 (Q2 2025) per Business Quant data.